Discovery and development of thiazolidine-2,4-dione derivatives as Bcl-2/Mcl-1 dual inhibitors

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Antiapoptotic B-cell lymphoma 2 (Bcl-2) proteins are crucial for cancer cell survival.
• Inhibiting Bcl-2 family proteins is a validated strategy for anticancer drug development.
• Mcl-1 is a key antiapoptotic protein and a significant therapeutic target in various cancers.

Purpose of the Study:

• To design and synthesize novel thiazolidine-2,4-dione analogs as Bcl-2/Mcl-1 inhibitors.
• To evaluate the inhibitory activity and selectivity of these analogs against antiapoptotic Bcl-2 proteins.
• To assess the potential of lead compounds as anticancer agents.

Main Methods:

• Synthesis of 39 thiazolidine-2,4-dione analogs with diverse substituents.
• In vitro assays to determine inhibitory activity against Bcl-2, Mcl-1, and Bcl-xL.
• Antiproliferative assays and apoptosis induction studies in cancer cell lines (U937).
• Western blot and co-immunoprecipitation to confirm mechanism of action.
• In vitro metabolic stability studies (rat plasma and liver microsomes).

Main Results:

• Compounds 16 and 20 demonstrated potent inhibition of Bcl-2 and Mcl-1, outperforming existing inhibitors.
• These compounds showed selectivity, with limited binding to Bcl-xL.
• Compound 20 exhibited significant antiproliferative effects and induced apoptosis in U937 cells.
• Mechanism of action confirmed through western blot and co-immunoprecipitation, showing on-target inhibition.
• Compound 20 displayed favorable metabolic stability in rat plasma and liver microsomes.

Conclusions:

• Compound 20 is a potent Bcl-2/Mcl-1 dual inhibitor with promising anticancer properties.
• The synthesized analogs represent a valuable class of compounds for developing novel cancer therapeutics.
• Compound 20 warrants further investigation as a lead candidate for anticancer drug discovery.